Korro Bio Inc. (KRRO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, KRRO scores 44 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Each of the five pillars is scored out of 20. The fundamental cash engine scores 8 / 20, reflecting an ROIC of -35% and an FCF yield of 0%. Whale 13F flow scores 12 / 20, which the rating attributes to institutional accumulation and options positioning. Insider conviction scores 3 / 20, citing SEC Form 4 and Congressional PTR cluster flow, the weakest pillar in the rating. Macro regime fit scores 13 / 20, based on a beta of 1.0 and sector sensitivity. Forensic balance sheet scores 8 / 20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5.

For a prospective investor, the picture is that the company's operating economics are deeply negative, with the cash engine pillar weak and insider conviction the lowest-scoring element. Any upside case would need to rest on the institutional accumulation signal and the sector's sensitivity to macro conditions rather than on current cash generation. The forensic metrics sit in a middle-to-weak zone, so balance-sheet resilience is a relevant consideration rather than a strength. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in the source data, leaving the investor to weigh a small market capitalization against sustained losses.

Per the SEC financials, reported operating and net losses are present across all three periods, with the FY 2025 operating loss of $-121.9M the largest in the table. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. The Roarable RQD rating records an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. Cash declined from $55.6M in FY 2024 to $21.8M in FY 2025 while FCF stayed negative, and debt figures are not available in source data.

• A Yahoo Finance headline reports KRRO surging 29.7%, flagged as a CATALYST (GREEN).
• An Investing.com item reports H.C. Wainwright reiterating its rating on trial dosing (MARKET WIRE, YELLOW).
• A Simply Wall St item asks whether the company will spend its cash wisely (MARKET WIRE, YELLOW), a headline that frames the cash-decline trend.
• Investing.com reports 10% owner Lynx1 Capital Management LP buying $884,751 of stock (MARKET WIRE, YELLOW).
• Stock Titan reports Lynx1 Master Fund buying 79,809 shares across three dates (MARKET WIRE, YELLOW).
• A report notes KRRO sliding 8.81% to $8.49, drifting toward key support (MARKET WIRE, YELLOW). This figure is a headline price and differs from the current price of $14.2 in the market data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What products or clinical programs drive the company's revenue and losses, given that the source data does not describe its business model?
• What is the company's debt position, since reported debt is N/A across all periods?
• How long can current cash of $21.8M fund operating losses of $-121.9M at the FY 2025 run rate?
• What are the specific holdings and transaction details behind the Lynx1 Capital and Lynx1 Master Fund purchases?
• Which catalysts, such as trial readouts, are scheduled, and how do they relate to the H.C. Wainwright rating reiteration?